Prognosis
U.S. Considers Concessions on Drug Protections in China Talks, Sources Say
- China said to offer eight years of biologics data protection
- Biologics now get 12 years of protection under American law
This article is for subscribers only.
The Trump administration may concede to a Chinese proposal that would give less protection for U.S. pharmaceutical products than they receive at home, according to people familiar with the matter, a move that could draw opposition from the American drug industry.
Under the Chinese offer being discussed as part of wider trade talks, U.S. pharmaceutical companies would get eight years of regulatory data protection in China for the biologics they develop, said two people, who spoke on condition of anonymity because the discussions are private.